Literature DB >> 11376399

Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases.

A E Siperstein1, E Berber.   

Abstract

Neuroendocrine liver metastases are associated with slow clinical progression, prolonged patient survival, and symptoms of hormone oversecretion. Although surgical resection is the gold standard of treatment, most of the patients are not candidates for resection, and the 5-year survival of patients with neuroendocrine liver metastases is 11% to 40%. Cryotherapy, percutaneous alcohol injection, and radiofrequency thermal ablation are among the alternative regional treatment options available for these patients. The current role of these treatment options for neuroendocrine liver tumors are discussed in this review. Cryosurgery is the classic technique for local tumor destruction, mostly performed with open surgery. There has been limited experience with percutaneous alcohol injection for neuroendocrine liver metastasis. Radiofrequency thermal ablation is a relatively new modality that can be performed percutaneously or laparoscopically, and encouraging results have been obtained with it for treatment of neuroendocrine liver metastases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376399     DOI: 10.1007/s00268-001-0015-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  19 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience.

Authors:  Emin Kose; Bora Kahramangil; Husnu Aydin; Mustafa Donmez; Hideo Takahashi; Federico Aucejo; Allan Siperstein; Eren Berber
Journal:  Surg Endosc       Date:  2019-04-03       Impact factor: 4.584

Review 3.  Treatment of liver metastases in patients with digestive neuroendocrine tumors.

Authors:  Roberta Elisa Rossi; Sara Massironi; Matilde Pia Spampatti; Dario Conte; Clorinda Ciafardini; Federica Cavalcoli; Maddalena Peracchi
Journal:  J Gastrointest Surg       Date:  2012-07-25       Impact factor: 3.452

4.  Pancreatic Neuroendocrine Tumors: an Update.

Authors:  Alessandro Paniccia; Barish H Edil; Richard D Schulick
Journal:  Indian J Surg       Date:  2015-10-13       Impact factor: 0.656

5.  Malignant metastatic insulinoma-postoperative treatment and follow-up.

Authors:  Achim Starke; Christiane Saddig; Lothar Mansfeld; Rainer Koester; Cyrus Tschahargane; Peter Czygan; Peter Goretzki
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

6.  Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.

Authors:  Xiang Da Dong; Brian I Carr
Journal:  Med Oncol       Date:  2010-11-24       Impact factor: 3.064

Review 7.  Radiofrequence ablation of liver cancers.

Authors:  Lian-Xin Liu; Hong-Chi Jiang; Da-Xun Piao
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

8.  Percutaneous radiofrequency thermal ablation of primary and metastatic hepatic tumors: current concepts and review of the literature.

Authors:  Aradhana M Venkatesan; Debra A Gervais; Peter R Mueller
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

9.  Cushing's syndrome due to ectopic adrenocorticotropic hormone production secondary to hepatic carcinoid: diagnosis, treatment, and improved quality of life.

Authors:  Susan G Coe; Winston W Tan; Thomas P Fox
Journal:  J Gen Intern Med       Date:  2008-04-02       Impact factor: 5.128

Review 10.  [Radiofrequency ablation of liver metastases].

Authors:  P L Pereira; S Clasen; A Boss; D Schmidt; C Gouttefangeas; C Burkart; J Wiskirchen; G Tepe; C D Claussen
Journal:  Radiologe       Date:  2004-04       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.